<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945867</url>
  </required_header>
  <id_info>
    <org_study_id>111/09</org_study_id>
    <nct_id>NCT00945867</nct_id>
  </id_info>
  <brief_title>Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy</brief_title>
  <official_title>The Use of CYP 450 2D6 Genotype as a Predictor of Flecainide Efficacy in the Treatment of Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The determination of the 2D6 genotype will enable us to determine the way flecainide is
      metabolized by the liver. Some individuals are poor metabolizers and some individuals are
      extensive metabolizers of the drug. This will also determine which patients will benefit from
      the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacogenetics is the study of genetic variations on drug metabolizing enzymes and
      transporters. Pharmacogenetics is one of the first clinical applications of the Human Genome
      Project. Pharmacogenomics is the study of the role of interindividual genomics variability on
      drug response, efficacy, and metabolism. It correlates the effects of the entire expressed
      genome to the clinical usefulness and toxicity of a drug. Pharmacogenomics has the potential
      to change the way patients' therapy is optimized, allowing an era of &quot;personalized medicine&quot;
      in which patients will be divided into groups based on genetic markers that treatment
      outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>no recurrence of atrial fibrillation</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the dose of flecainide used</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atrial fibrillation and a normal heart.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with recurrent AF

          -  Patients with a structurally normal heart

          -  Patients &gt; 18 YO

          -  Patients who signed an informed consent

        Exclusion Criteria:

          -  Renal failure with creatinine clearance less than 40

          -  Elevated liver enzymes 3 times the normal range, or causing coagulation test
             abnormality

          -  Pregnant patients

          -  Patients treated with psychiatric agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Sharist, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shmuel Bar-Haim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Therese Fuchs, MD</last_name>
    <phone>972-8-977-8179</phone>
    <email>fuchst@asaf.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <zip>00000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Therese Fuchs, MD</last_name>
      <phone>972-8-977-8179</phone>
      <email>fuchst@asaf.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Moshe Sharist, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>April 4, 2011</last_update_submitted>
  <last_update_submitted_qc>April 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Therese Fuchs, MD</name_title>
    <organization>Assaf Harofeh Medical Center</organization>
  </responsible_party>
  <keyword>flecainide</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

